ES2616095T3 - Derivados de 2-(1H-indolilsulfanil)-aril-amina - Google Patents
Derivados de 2-(1H-indolilsulfanil)-aril-amina Download PDFInfo
- Publication number
- ES2616095T3 ES2616095T3 ES06808965.5T ES06808965T ES2616095T3 ES 2616095 T3 ES2616095 T3 ES 2616095T3 ES 06808965 T ES06808965 T ES 06808965T ES 2616095 T3 ES2616095 T3 ES 2616095T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- phenyl
- ylsulfanyl
- amine
- indol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 1H-indolylsulfanyl Chemical group 0.000 title claims description 44
- 150000001875 compounds Chemical class 0.000 claims abstract description 170
- 150000003839 salts Chemical class 0.000 claims abstract description 51
- 239000001257 hydrogen Substances 0.000 claims abstract description 43
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 43
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 33
- 150000002367 halogens Chemical group 0.000 claims abstract description 33
- 239000012458 free base Substances 0.000 claims abstract description 29
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 26
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 18
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 14
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 13
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000001301 oxygen Substances 0.000 claims abstract description 10
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 10
- 239000011593 sulfur Chemical group 0.000 claims abstract description 10
- 229910052717 sulfur Chemical group 0.000 claims abstract description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims description 41
- 238000011282 treatment Methods 0.000 claims description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 19
- 230000005764 inhibitory process Effects 0.000 claims description 18
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 17
- 208000035475 disorder Diseases 0.000 claims description 17
- 229960002748 norepinephrine Drugs 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 16
- 208000020401 Depressive disease Diseases 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 229940076279 serotonin Drugs 0.000 claims description 12
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 11
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims description 11
- 208000019901 Anxiety disease Diseases 0.000 claims description 10
- 208000019022 Mood disease Diseases 0.000 claims description 10
- 208000002193 Pain Diseases 0.000 claims description 10
- 230000009286 beneficial effect Effects 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 9
- 208000027520 Somatoform disease Diseases 0.000 claims description 8
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 8
- 208000027753 pain disease Diseases 0.000 claims description 8
- 239000000221 dopamine uptake inhibitor Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims description 7
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 claims description 6
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 6
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims description 5
- 206010041250 Social phobia Diseases 0.000 claims description 5
- 208000017194 Affective disease Diseases 0.000 claims description 4
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 claims description 4
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 claims description 4
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 claims description 4
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 claims description 4
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 claims description 4
- 208000019906 panic disease Diseases 0.000 claims description 4
- DQPAGLBQGKUVKT-UHFFFAOYSA-N 2-[2-(1h-indol-3-ylsulfanyl)-4,5-dimethoxyphenyl]-n-methylethanamine Chemical compound CNCCC1=CC(OC)=C(OC)C=C1SC1=CNC2=CC=CC=C12 DQPAGLBQGKUVKT-UHFFFAOYSA-N 0.000 claims description 3
- ICPDRZWPWMKFRH-UHFFFAOYSA-N 2-[2-(1h-indol-3-ylsulfanyl)phenyl]-n,n-dimethylethanamine Chemical compound CN(C)CCC1=CC=CC=C1SC1=CNC2=CC=CC=C12 ICPDRZWPWMKFRH-UHFFFAOYSA-N 0.000 claims description 3
- WLCRVWHOFBNTLR-UHFFFAOYSA-N 2-[2-(1h-indol-3-ylsulfanyl)phenyl]-n-methylethanamine Chemical compound CNCCC1=CC=CC=C1SC1=CNC2=CC=CC=C12 WLCRVWHOFBNTLR-UHFFFAOYSA-N 0.000 claims description 3
- BWNTWPVXUBOGTA-UHFFFAOYSA-N 2-[2-[(4-chloro-1h-indol-3-yl)sulfanyl]-4,5-dimethoxyphenyl]-n-methylethanamine Chemical compound CNCCC1=CC(OC)=C(OC)C=C1SC1=CNC2=CC=CC(Cl)=C12 BWNTWPVXUBOGTA-UHFFFAOYSA-N 0.000 claims description 3
- RIMCVADQHDOBGR-UHFFFAOYSA-N 2-[2-[(4-chloro-1h-indol-3-yl)sulfanyl]phenyl]-n-methylethanamine Chemical compound CNCCC1=CC=CC=C1SC1=CNC2=CC=CC(Cl)=C12 RIMCVADQHDOBGR-UHFFFAOYSA-N 0.000 claims description 3
- YJWYWKYCWYOLHL-UHFFFAOYSA-N 2-[2-[(4-fluoro-1h-indol-3-yl)sulfanyl]phenyl]-n-methylethanamine Chemical compound CNCCC1=CC=CC=C1SC1=CNC2=CC=CC(F)=C12 YJWYWKYCWYOLHL-UHFFFAOYSA-N 0.000 claims description 3
- AXVBUKGLIRZPDO-UHFFFAOYSA-N 2-[2-[(5-chloro-1h-indol-3-yl)sulfanyl]phenyl]-n-methylethanamine Chemical compound CNCCC1=CC=CC=C1SC1=CNC2=CC=C(Cl)C=C12 AXVBUKGLIRZPDO-UHFFFAOYSA-N 0.000 claims description 3
- QJQJODCAYMBBOA-UHFFFAOYSA-N 2-[2-[(6-fluoro-1h-indol-3-yl)sulfanyl]phenyl]-n-methylethanamine Chemical compound CNCCC1=CC=CC=C1SC1=CNC2=CC(F)=CC=C12 QJQJODCAYMBBOA-UHFFFAOYSA-N 0.000 claims description 3
- RNBZMVSYRDYWPZ-UHFFFAOYSA-N 2-[2-[(7-fluoro-1h-indol-3-yl)sulfanyl]phenyl]-n-methylethanamine Chemical compound CNCCC1=CC=CC=C1SC1=CNC2=C(F)C=CC=C12 RNBZMVSYRDYWPZ-UHFFFAOYSA-N 0.000 claims description 3
- YOOGDLBGZBCOOL-UHFFFAOYSA-N 2-[2-[(7-methoxy-1h-indol-3-yl)sulfanyl]phenyl]-n-methylethanamine Chemical compound CNCCC1=CC=CC=C1SC1=CNC2=C(OC)C=CC=C12 YOOGDLBGZBCOOL-UHFFFAOYSA-N 0.000 claims description 3
- JZOKUXUBUSALFY-UHFFFAOYSA-N 2-[5-chloro-2-(1h-indol-3-ylsulfanyl)phenyl]-n-methylethanamine Chemical compound CNCCC1=CC(Cl)=CC=C1SC1=CNC2=CC=CC=C12 JZOKUXUBUSALFY-UHFFFAOYSA-N 0.000 claims description 3
- KNBQBLWRNYUVAH-UHFFFAOYSA-N 2-[5-chloro-2-[(4-chloro-1h-indol-3-yl)sulfanyl]phenyl]-n-methylethanamine Chemical compound CNCCC1=CC(Cl)=CC=C1SC1=CNC2=CC=CC(Cl)=C12 KNBQBLWRNYUVAH-UHFFFAOYSA-N 0.000 claims description 3
- LNKSUCWXHZGBGF-UHFFFAOYSA-N 2-[5-fluoro-2-(1h-indol-3-ylsulfanyl)phenyl]-n-methylethanamine Chemical compound CNCCC1=CC(F)=CC=C1SC1=CNC2=CC=CC=C12 LNKSUCWXHZGBGF-UHFFFAOYSA-N 0.000 claims description 3
- SRDPGAAMUNUOIS-UHFFFAOYSA-N 3-[2-[(4-chloro-1h-indol-3-yl)sulfanyl]phenyl]-n-methylpropan-1-amine Chemical compound CNCCCC1=CC=CC=C1SC1=CNC2=CC=CC(Cl)=C12 SRDPGAAMUNUOIS-UHFFFAOYSA-N 0.000 claims description 3
- MVBGNZJNMIRAMA-UHFFFAOYSA-N 3-[2-[(4-methoxy-1h-indol-3-yl)sulfanyl]phenyl]-n-methylpropan-1-amine Chemical compound CNCCCC1=CC=CC=C1SC1=CNC2=CC=CC(OC)=C12 MVBGNZJNMIRAMA-UHFFFAOYSA-N 0.000 claims description 3
- BTRYKXYPTODPPY-UHFFFAOYSA-N 4-[2-(1h-indol-3-ylsulfanyl)phenyl]-n-methylbutan-1-amine Chemical compound CNCCCCC1=CC=CC=C1SC1=CNC2=CC=CC=C12 BTRYKXYPTODPPY-UHFFFAOYSA-N 0.000 claims description 3
- SRHYNMGXVHXWBZ-UHFFFAOYSA-N 4-[2-[(4-chloro-1h-indol-3-yl)sulfanyl]phenyl]-n-methylbutan-1-amine Chemical compound CNCCCCC1=CC=CC=C1SC1=CNC2=CC=CC(Cl)=C12 SRHYNMGXVHXWBZ-UHFFFAOYSA-N 0.000 claims description 3
- 208000008035 Back Pain Diseases 0.000 claims description 3
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 3
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims description 3
- 208000007613 Shoulder Pain Diseases 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- JYQNIYWKCHAIJP-UHFFFAOYSA-N n,n-dimethyl-3-[2-[3-(methylamino)propyl]phenyl]sulfanyl-1h-indol-5-amine Chemical compound CNCCCC1=CC=CC=C1SC1=CNC2=CC=C(N(C)C)C=C12 JYQNIYWKCHAIJP-UHFFFAOYSA-N 0.000 claims description 3
- SAHZVUTZRRRCOC-UHFFFAOYSA-N n-methyl-4-[2-(1-methylindol-3-yl)sulfanylphenyl]butan-1-amine Chemical compound CNCCCCC1=CC=CC=C1SC1=CN(C)C2=CC=CC=C12 SAHZVUTZRRRCOC-UHFFFAOYSA-N 0.000 claims description 3
- FFQRPQADRFJXBR-UHFFFAOYSA-N 2-[2-[(5-fluoro-1h-indol-3-yl)sulfanyl]phenyl]-n-methylethanamine Chemical compound CNCCC1=CC=CC=C1SC1=CNC2=CC=C(F)C=C12 FFQRPQADRFJXBR-UHFFFAOYSA-N 0.000 claims description 2
- MAQJERMHYZHZNQ-UHFFFAOYSA-N 2-[2-[(5-fluoro-2-methyl-1h-indol-3-yl)sulfanyl]phenyl]-n-methylethanamine Chemical compound CNCCC1=CC=CC=C1SC1=C(C)NC2=CC=C(F)C=C12 MAQJERMHYZHZNQ-UHFFFAOYSA-N 0.000 claims description 2
- DMVJPZPTGURZBL-UHFFFAOYSA-N 2-[2-[(6-fluoro-1h-indol-3-yl)sulfanyl]-4,5-dimethoxyphenyl]-n-methylethanamine Chemical compound CNCCC1=CC(OC)=C(OC)C=C1SC1=CNC2=CC(F)=CC=C12 DMVJPZPTGURZBL-UHFFFAOYSA-N 0.000 claims description 2
- DWYLAMVKASXSQL-UHFFFAOYSA-N 2-[2-[(7-chloro-1h-indol-3-yl)sulfanyl]phenyl]-n-methylethanamine Chemical compound CNCCC1=CC=CC=C1SC1=CNC2=C(Cl)C=CC=C12 DWYLAMVKASXSQL-UHFFFAOYSA-N 0.000 claims description 2
- WHGGCUWEVUVLDC-UHFFFAOYSA-N 2-[5-chloro-2-[(6-fluoro-1h-indol-3-yl)sulfanyl]phenyl]-n-methylethanamine Chemical compound CNCCC1=CC(Cl)=CC=C1SC1=CNC2=CC(F)=CC=C12 WHGGCUWEVUVLDC-UHFFFAOYSA-N 0.000 claims description 2
- MFAKBZPNIWVEKG-UHFFFAOYSA-N 3-[2-(1h-indol-3-ylsulfanyl)phenyl]-n-methylpropan-1-amine Chemical compound CNCCCC1=CC=CC=C1SC1=CNC2=CC=CC=C12 MFAKBZPNIWVEKG-UHFFFAOYSA-N 0.000 claims description 2
- DYUYSUSCPXONTN-UHFFFAOYSA-N 3-[2-[(6-fluoro-1h-indol-3-yl)sulfanyl]phenyl]-n-methylpropan-1-amine Chemical compound CNCCCC1=CC=CC=C1SC1=CNC2=CC(F)=CC=C12 DYUYSUSCPXONTN-UHFFFAOYSA-N 0.000 claims description 2
- ZHDDBWQTGUSZCV-UHFFFAOYSA-N 4-[2-[(4-methoxy-1h-indol-3-yl)sulfanyl]phenyl]-n-methylbutan-1-amine Chemical compound CNCCCCC1=CC=CC=C1SC1=CNC2=CC=CC(OC)=C12 ZHDDBWQTGUSZCV-UHFFFAOYSA-N 0.000 claims description 2
- 208000008811 Agoraphobia Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 206010033664 Panic attack Diseases 0.000 claims description 2
- 206010034912 Phobia Diseases 0.000 claims description 2
- 201000009916 Postpartum depression Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 230000006735 deficit Effects 0.000 claims description 2
- 208000024732 dysthymic disease Diseases 0.000 claims description 2
- 208000013403 hyperactivity Diseases 0.000 claims description 2
- 208000024714 major depressive disease Diseases 0.000 claims description 2
- CEFGTUXAYJORMD-UHFFFAOYSA-N n-methyl-3-[2-(1-methylindol-3-yl)sulfanylphenyl]propan-1-amine Chemical compound CNCCCC1=CC=CC=C1SC1=CN(C)C2=CC=CC=C12 CEFGTUXAYJORMD-UHFFFAOYSA-N 0.000 claims description 2
- SOPCKTHZILILCA-UHFFFAOYSA-N n-methyl-3-[2-[(5-methyl-1h-indol-3-yl)sulfanyl]phenyl]propan-1-amine Chemical compound CNCCCC1=CC=CC=C1SC1=CNC2=CC=C(C)C=C12 SOPCKTHZILILCA-UHFFFAOYSA-N 0.000 claims description 2
- RRGXUXYKXPHPDF-UHFFFAOYSA-N n-methyl-3-[2-[(6-methylsulfonyl-1h-indol-3-yl)sulfanyl]phenyl]propan-1-amine Chemical compound CNCCCC1=CC=CC=C1SC1=CNC2=CC(S(C)(=O)=O)=CC=C12 RRGXUXYKXPHPDF-UHFFFAOYSA-N 0.000 claims description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
- 201000001716 specific phobia Diseases 0.000 claims description 2
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 101100495914 Arabidopsis thaliana ETL1 gene Proteins 0.000 abstract 1
- 101100243950 Arabidopsis thaliana PIE1 gene Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 description 76
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- 238000002360 preparation method Methods 0.000 description 41
- 239000000203 mixture Substances 0.000 description 34
- 239000002253 acid Substances 0.000 description 32
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000003112 inhibitor Substances 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
- 235000019341 magnesium sulphate Nutrition 0.000 description 12
- 150000003573 thiols Chemical group 0.000 description 12
- 239000000543 intermediate Substances 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000000935 antidepressant agent Substances 0.000 description 10
- 210000005080 cortical synaptosome Anatomy 0.000 description 10
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 229940005513 antidepressants Drugs 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 9
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 8
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Substances ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 7
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 7
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 7
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 7
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 239000011737 fluorine Substances 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 239000011630 iodine Substances 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000006187 pill Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 7
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 230000000697 serotonin reuptake Effects 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 5
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 5
- LTYMSROWYAPPGB-UHFFFAOYSA-N diphenyl sulfide Chemical class C=1C=CC=CC=1SC1=CC=CC=C1 LTYMSROWYAPPGB-UHFFFAOYSA-N 0.000 description 5
- 229960002866 duloxetine Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 125000005246 nonafluorobutyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 description 5
- 125000002577 pseudohalo group Chemical group 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 5
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 5
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 5
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 4
- 238000000105 evaporative light scattering detection Methods 0.000 description 4
- IKGLACJFEHSFNN-UHFFFAOYSA-N hydron;triethylazanium;trifluoride Chemical compound F.F.F.CCN(CC)CC IKGLACJFEHSFNN-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- 238000006053 organic reaction Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- FWMUJAIKEJWSSY-UHFFFAOYSA-N sulfur dichloride Chemical compound ClSCl FWMUJAIKEJWSSY-UHFFFAOYSA-N 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 4
- 229960004688 venlafaxine Drugs 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 3
- OIRHKGBNGGSCGS-UHFFFAOYSA-N 1-bromo-2-iodobenzene Chemical compound BrC1=CC=CC=C1I OIRHKGBNGGSCGS-UHFFFAOYSA-N 0.000 description 3
- HINCFRLYGPUTAV-UHFFFAOYSA-N 2-[2-(1h-indol-3-ylsulfanyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC=C1SC1=CNC2=CC=CC=C12 HINCFRLYGPUTAV-UHFFFAOYSA-N 0.000 description 3
- SJEICXUOVUJKCZ-UHFFFAOYSA-N 2-[5-fluoro-2-(1H-indol-3-ylsulfanyl)phenyl]ethyl-methylcarbamic acid Chemical compound FC=1C=CC(=C(C=1)CCN(C(O)=O)C)SC1=CNC2=CC=CC=C12 SJEICXUOVUJKCZ-UHFFFAOYSA-N 0.000 description 3
- LUNOXNMCFPFPMO-UHFFFAOYSA-N 4-methoxy-1h-indole Chemical compound COC1=CC=CC2=C1C=CN2 LUNOXNMCFPFPMO-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 201000001880 Sexual dysfunction Diseases 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- RYXZOQOZERSHHQ-UHFFFAOYSA-N [2-(2-diphenylphosphanylphenoxy)phenyl]-diphenylphosphane Chemical compound C=1C=CC=C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)C=1OC1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RYXZOQOZERSHHQ-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229960001653 citalopram Drugs 0.000 description 3
- 230000002301 combined effect Effects 0.000 description 3
- 229960004132 diethyl ether Drugs 0.000 description 3
- 230000002825 dopamine reuptake Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 150000002475 indoles Chemical class 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000000966 norepinephrine reuptake Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 3
- 231100000872 sexual dysfunction Toxicity 0.000 description 3
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- WMKGGPCROCCUDY-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one Chemical compound C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 WMKGGPCROCCUDY-UHFFFAOYSA-N 0.000 description 2
- BLRHMMGNCXNXJL-UHFFFAOYSA-N 1-methylindole Chemical compound C1=CC=C2N(C)C=CC2=C1 BLRHMMGNCXNXJL-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- ZCBIFHNDZBSCEP-UHFFFAOYSA-N 1H-indol-5-amine Chemical compound NC1=CC=C2NC=CC2=C1 ZCBIFHNDZBSCEP-UHFFFAOYSA-N 0.000 description 2
- MDOLAGJKKZEHHW-UHFFFAOYSA-N 2-(2-bromo-4,5-dimethoxyphenyl)acetic acid Chemical compound COC1=CC(Br)=C(CC(O)=O)C=C1OC MDOLAGJKKZEHHW-UHFFFAOYSA-N 0.000 description 2
- ZPSZXWVBMOMXED-UHFFFAOYSA-N 2-(2-bromo-5-chlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC(Cl)=CC=C1Br ZPSZXWVBMOMXED-UHFFFAOYSA-N 0.000 description 2
- YQLRTCNMMVXNSJ-UHFFFAOYSA-N 2-(2-bromo-5-fluorophenyl)-n-methylacetamide Chemical compound CNC(=O)CC1=CC(F)=CC=C1Br YQLRTCNMMVXNSJ-UHFFFAOYSA-N 0.000 description 2
- XNSWJIIYPWPPEE-UHFFFAOYSA-N 2-(2-bromo-5-fluorophenyl)-n-methylethanamine Chemical compound CNCCC1=CC(F)=CC=C1Br XNSWJIIYPWPPEE-UHFFFAOYSA-N 0.000 description 2
- BPNWLZNAKZSBHH-UHFFFAOYSA-N 2-(2-bromo-5-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC(F)=CC=C1Br BPNWLZNAKZSBHH-UHFFFAOYSA-N 0.000 description 2
- DWXSYDKEWORWBT-UHFFFAOYSA-N 2-(2-bromophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1Br DWXSYDKEWORWBT-UHFFFAOYSA-N 0.000 description 2
- IUHXGZHKSYYDIL-UHFFFAOYSA-N 2-(2-iodophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1I IUHXGZHKSYYDIL-UHFFFAOYSA-N 0.000 description 2
- ZVRXWCHVOIXFSH-UHFFFAOYSA-N 2-[5-fluoro-2-[(6-fluoro-1h-indol-3-yl)sulfanyl]phenyl]-n-methylethanamine Chemical compound CNCCC1=CC(F)=CC=C1SC1=CNC2=CC(F)=CC=C12 ZVRXWCHVOIXFSH-UHFFFAOYSA-N 0.000 description 2
- PWYVMZNIBZFIAR-UHFFFAOYSA-N 2-[5-fluoro-2-tri(propan-2-yl)silylsulfanylphenyl]ethyl-methylcarbamic acid Chemical compound CC(C)[Si](C(C)C)(C(C)C)SC1=C(C=C(C=C1)F)CCN(C)C(=O)O PWYVMZNIBZFIAR-UHFFFAOYSA-N 0.000 description 2
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- AOACQJFIGWNQBC-UHFFFAOYSA-N 3-(2-bromophenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=CC=C1Br AOACQJFIGWNQBC-UHFFFAOYSA-N 0.000 description 2
- ZSPTYLOMNJNZNG-UHFFFAOYSA-N 3-Buten-1-ol Chemical compound OCCC=C ZSPTYLOMNJNZNG-UHFFFAOYSA-N 0.000 description 2
- FPZQJVZMZMHOGC-UHFFFAOYSA-N 4-(2-bromophenyl)butanenitrile Chemical compound BrC1=CC=CC=C1CCCC#N FPZQJVZMZMHOGC-UHFFFAOYSA-N 0.000 description 2
- SVLZRCRXNHITBY-UHFFFAOYSA-N 4-chloro-1h-indole Chemical compound ClC1=CC=CC2=C1C=CN2 SVLZRCRXNHITBY-UHFFFAOYSA-N 0.000 description 2
- ZWKIJOPJWWZLDI-UHFFFAOYSA-N 4-fluoro-1h-indole Chemical compound FC1=CC=CC2=C1C=CN2 ZWKIJOPJWWZLDI-UHFFFAOYSA-N 0.000 description 2
- MYTGFBZJLDLWQG-UHFFFAOYSA-N 5-chloro-1h-indole Chemical compound ClC1=CC=C2NC=CC2=C1 MYTGFBZJLDLWQG-UHFFFAOYSA-N 0.000 description 2
- ODFFPRGJZRXNHZ-UHFFFAOYSA-N 5-fluoroindole Chemical compound FC1=CC=C2NC=CC2=C1 ODFFPRGJZRXNHZ-UHFFFAOYSA-N 0.000 description 2
- YYFFEPUCAKVRJX-UHFFFAOYSA-N 6-fluoro-1h-indole Chemical compound FC1=CC=C2C=CNC2=C1 YYFFEPUCAKVRJX-UHFFFAOYSA-N 0.000 description 2
- WMYQAKANKREQLM-UHFFFAOYSA-N 7-chloro-1h-indole Chemical compound ClC1=CC=CC2=C1NC=C2 WMYQAKANKREQLM-UHFFFAOYSA-N 0.000 description 2
- XONKJZDHGCMRRF-UHFFFAOYSA-N 7-fluoro-1h-indole Chemical compound FC1=CC=CC2=C1NC=C2 XONKJZDHGCMRRF-UHFFFAOYSA-N 0.000 description 2
- FSOPPXYMWZOKRM-UHFFFAOYSA-N 7-methoxy-1h-indole Chemical compound COC1=CC=CC2=C1NC=C2 FSOPPXYMWZOKRM-UHFFFAOYSA-N 0.000 description 2
- LZJGQIVWUKFTRD-UHFFFAOYSA-N 7-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=CC2=C1NC=C2 LZJGQIVWUKFTRD-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- GENKOKXKNZMVPE-UHFFFAOYSA-N BrC1=C(C=C(C=C1)F)CCN(C(=O)O)C Chemical compound BrC1=C(C=C(C=C1)F)CCN(C(=O)O)C GENKOKXKNZMVPE-UHFFFAOYSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- OXTVKQWHJOCJOU-UHFFFAOYSA-N FC=1C=CC(=C(C1)CCN(C(=O)O)C)S Chemical compound FC=1C=CC(=C(C1)CCN(C(=O)O)C)S OXTVKQWHJOCJOU-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229910010084 LiAlH4 Inorganic materials 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000000035 biogenic effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012320 chlorinating reagent Substances 0.000 description 2
- 229960003368 croscarmellose sodium type a Drugs 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Chemical class 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- NNOAPVNVZFDCOT-UHFFFAOYSA-N n-methyl-2-[2-(1-methylindol-3-yl)sulfanylphenyl]ethanamine Chemical compound CNCCC1=CC=CC=C1SC1=CN(C)C2=CC=CC=C12 NNOAPVNVZFDCOT-UHFFFAOYSA-N 0.000 description 2
- CWIYQMMAQKQXCL-UHFFFAOYSA-N n-methyl-3-[2-[(7-nitro-1h-indol-3-yl)sulfanyl]phenyl]propan-1-amine Chemical compound CNCCCC1=CC=CC=C1SC1=CNC2=C([N+]([O-])=O)C=CC=C12 CWIYQMMAQKQXCL-UHFFFAOYSA-N 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000013275 serotonin uptake Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 125000006553 (C3-C8) cycloalkenyl group Chemical group 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- LOJZXXNBYMQLDW-UHFFFAOYSA-N 2-(2-bromo-4,5-dimethoxyphenyl)-n-methylacetamide Chemical compound CNC(=O)CC1=CC(OC)=C(OC)C=C1Br LOJZXXNBYMQLDW-UHFFFAOYSA-N 0.000 description 1
- FHDOOUJHFQIHAM-UHFFFAOYSA-N 2-(2-bromo-4,5-dimethoxyphenyl)-n-methylethanamine Chemical compound CNCCC1=CC(OC)=C(OC)C=C1Br FHDOOUJHFQIHAM-UHFFFAOYSA-N 0.000 description 1
- OPTFNJIKXWSCGJ-UHFFFAOYSA-N 2-(2-bromo-4,5-dimethoxyphenyl)ethyl-methylcarbamic acid Chemical compound COC1=CC(Br)=C(CCN(C)C(O)=O)C=C1OC OPTFNJIKXWSCGJ-UHFFFAOYSA-N 0.000 description 1
- MUZOFJNSWZBZJP-UHFFFAOYSA-N 2-(2-bromo-5-chlorophenyl)-n-methylacetamide Chemical compound CNC(=O)CC1=CC(Cl)=CC=C1Br MUZOFJNSWZBZJP-UHFFFAOYSA-N 0.000 description 1
- DVPCBYBIXZBALJ-UHFFFAOYSA-N 2-(2-bromo-5-chlorophenyl)-n-methylethanamine Chemical compound CNCCC1=CC(Cl)=CC=C1Br DVPCBYBIXZBALJ-UHFFFAOYSA-N 0.000 description 1
- BPCCKSZFAYPYAB-UHFFFAOYSA-N 2-(2-bromo-5-chlorophenyl)ethyl-methylcarbamic acid Chemical compound BrC1=C(C=C(C=C1)Cl)CCN(C(O)=O)C BPCCKSZFAYPYAB-UHFFFAOYSA-N 0.000 description 1
- OTFFWVKSMZZNRH-UHFFFAOYSA-N 2-(2-iodophenyl)-n-methylacetamide Chemical compound CNC(=O)CC1=CC=CC=C1I OTFFWVKSMZZNRH-UHFFFAOYSA-N 0.000 description 1
- BSTPKKWTQDFQCS-UHFFFAOYSA-N 2-(2-iodophenyl)-n-methylethanamine Chemical compound CNCCC1=CC=CC=C1I BSTPKKWTQDFQCS-UHFFFAOYSA-N 0.000 description 1
- IAAXAMZKTGALFH-UHFFFAOYSA-N 2-(2-iodophenyl)ethyl-methylcarbamic acid Chemical compound IC1=C(C=CC=C1)CCN(C(O)=O)C IAAXAMZKTGALFH-UHFFFAOYSA-N 0.000 description 1
- QUCMZSJETXEAMC-UHFFFAOYSA-N 2-(2-sulfanylphenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1S QUCMZSJETXEAMC-UHFFFAOYSA-N 0.000 description 1
- ZFJFABIZJJEBSD-UHFFFAOYSA-N 2-(4,5-dimethoxy-2-sulfanylphenyl)ethyl-methylcarbamic acid Chemical compound SC1=C(C=C(C(=C1)OC)OC)CCN(C(O)=O)C ZFJFABIZJJEBSD-UHFFFAOYSA-N 0.000 description 1
- GYPKJHAIYCOVKJ-UHFFFAOYSA-N 2-(5-chloro-2-sulfanylphenyl)ethyl-methylcarbamic acid Chemical compound ClC=1C=CC(=C(C1)CCN(C(=O)O)C)S GYPKJHAIYCOVKJ-UHFFFAOYSA-N 0.000 description 1
- KRDZDTUILFJNEJ-UHFFFAOYSA-N 2-[2-(1h-indol-3-ylsulfanyl)phenyl]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CC1=CC=CC=C1SC1=CNC2=CC=CC=C12 KRDZDTUILFJNEJ-UHFFFAOYSA-N 0.000 description 1
- QIZHYLRNYNSPCV-UHFFFAOYSA-N 2-[2-[(4-chloro-1h-indol-3-yl)sulfanyl]-5-fluorophenyl]-n-methylethanamine Chemical compound CNCCC1=CC(F)=CC=C1SC1=CNC2=CC=CC(Cl)=C12 QIZHYLRNYNSPCV-UHFFFAOYSA-N 0.000 description 1
- JETMRZVVYHJSRK-UHFFFAOYSA-N 2-[2-tri(propan-2-yl)silylsulfanylphenyl]acetic acid Chemical compound CC(C)[Si](C(C)C)(C(C)C)SC1=CC=CC=C1CC(=O)O JETMRZVVYHJSRK-UHFFFAOYSA-N 0.000 description 1
- VODAJGPTULSNSU-UHFFFAOYSA-N 3-(2-bromophenyl)propan-1-ol Chemical compound OCCCC1=CC=CC=C1Br VODAJGPTULSNSU-UHFFFAOYSA-N 0.000 description 1
- LZYQKMVDCBFOOX-UHFFFAOYSA-N 3-(2-bromophenyl)propanal Chemical compound BrC1=CC=CC=C1CCC=O LZYQKMVDCBFOOX-UHFFFAOYSA-N 0.000 description 1
- FKHYYOUFMJBLAF-UHFFFAOYSA-N 3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)-n-methylpropan-1-amine Chemical compound S1C(C)(C)C2=CC=CC=C2C1(CCCNC)C1=CC=CC=C1 FKHYYOUFMJBLAF-UHFFFAOYSA-N 0.000 description 1
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
- DBWHNNFKEKSZAD-UHFFFAOYSA-N 4-(2-bromophenyl)-n-methylbutan-1-amine Chemical compound CNCCCCC1=CC=CC=C1Br DBWHNNFKEKSZAD-UHFFFAOYSA-N 0.000 description 1
- RAMTXKLUFGFWMW-UHFFFAOYSA-N 4-(2-bromophenyl)butyl-methylcarbamic acid Chemical compound BrC1=C(C=CC=C1)CCCCN(C(O)=O)C RAMTXKLUFGFWMW-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-CMIMLBRMSA-N 4-[(1r)-2-amino-1-hydroxy-1-tritioethyl]benzene-1,2-diol Chemical compound NC[C@@](O)([3H])C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-CMIMLBRMSA-N 0.000 description 1
- BJYPYNKXPNCMAG-UHFFFAOYSA-N 4-[2-[2-(1h-indol-3-ylsulfanyl)phenyl]ethyl]morpholine Chemical compound C=1C=CC=C(SC=2C3=CC=CC=C3NC=2)C=1CCN1CCOCC1 BJYPYNKXPNCMAG-UHFFFAOYSA-N 0.000 description 1
- QLXNOQBWMYRPJE-UHFFFAOYSA-N 4-[2-[2-(1h-indol-3-ylsulfanyl)phenyl]ethyl]thiomorpholine Chemical compound C=1C=CC=C(SC=2C3=CC=CC=C3NC=2)C=1CCN1CCSCC1 QLXNOQBWMYRPJE-UHFFFAOYSA-N 0.000 description 1
- ODGJXOWMYWXXJD-UHFFFAOYSA-N 5-fluoro-7-methyl-1h-indole Chemical compound CC1=CC(F)=CC2=C1NC=C2 ODGJXOWMYWXXJD-UHFFFAOYSA-N 0.000 description 1
- 210000002348 5-ht neuron Anatomy 0.000 description 1
- CGPAQJHSHAIUQG-UHFFFAOYSA-N 6-methylsulfonyl-1h-indole Chemical compound CS(=O)(=O)C1=CC=C2C=CNC2=C1 CGPAQJHSHAIUQG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 description 1
- MAIJRIQHUYZOPD-UHFFFAOYSA-N C(C)(C)(C)OC(N(C)CCC1=C(C=CC=C1)SC1=CNC2=CC=CC(=C12)Cl)=O.C(C)(C)(C)OC(N(C)CCC1=C(C=CC=C1)SC1=CNC2=CC=C(C=C12)Cl)=O Chemical compound C(C)(C)(C)OC(N(C)CCC1=C(C=CC=C1)SC1=CNC2=CC=CC(=C12)Cl)=O.C(C)(C)(C)OC(N(C)CCC1=C(C=CC=C1)SC1=CNC2=CC=C(C=C12)Cl)=O MAIJRIQHUYZOPD-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 201000002380 X-linked amelogenesis imperfecta hypoplastic/hypomaturation 2 Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 1
- 229960001081 benzatropine Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 229960001149 dopamine hydrochloride Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- ILPJITNIMGVOHA-UHFFFAOYSA-N n,n-diethylethanamine;ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O.CCN(CC)CC ILPJITNIMGVOHA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960003057 nialamide Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000012154 norepinephrine uptake Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000009057 passive transport Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- JWUKZUIGOJBEPC-UHFFFAOYSA-N phenyl thiohypochlorite Chemical class ClSC1=CC=CC=C1 JWUKZUIGOJBEPC-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
- 229960003770 reboxetine Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229950002139 talsupram Drugs 0.000 description 1
- XNKMRNDWVZVMBM-UHFFFAOYSA-N tert-butyl n-[2-[2-[(4-chloro-1h-indol-3-yl)sulfanyl]-4,5-dimethoxyphenyl]ethyl]-n-methylcarbamate Chemical compound C1=C(OC)C(OC)=CC(CCN(C)C(=O)OC(C)(C)C)=C1SC1=CNC2=CC=CC(Cl)=C12 XNKMRNDWVZVMBM-UHFFFAOYSA-N 0.000 description 1
- CLLWRMTTWUXYCR-UHFFFAOYSA-N tert-butyl n-[2-[2-[(5-fluoro-1h-indol-3-yl)sulfanyl]phenyl]ethyl]-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)CCC1=CC=CC=C1SC1=CNC2=CC=C(F)C=C12 CLLWRMTTWUXYCR-UHFFFAOYSA-N 0.000 description 1
- GWHHJWMYVLUBFL-UHFFFAOYSA-N tert-butyl n-[2-[2-[(6-fluoro-1h-indol-3-yl)sulfanyl]-4,5-dimethoxyphenyl]ethyl]-n-methylcarbamate Chemical compound C1=C(OC)C(OC)=CC(CCN(C)C(=O)OC(C)(C)C)=C1SC1=CNC2=CC(F)=CC=C12 GWHHJWMYVLUBFL-UHFFFAOYSA-N 0.000 description 1
- QSRCKMZEVOEMNG-UHFFFAOYSA-N tert-butyl n-[2-[5-fluoro-2-[(6-fluoro-1h-indol-3-yl)sulfanyl]phenyl]ethyl]-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)CCC1=CC(F)=CC=C1SC1=CNC2=CC(F)=CC=C12 QSRCKMZEVOEMNG-UHFFFAOYSA-N 0.000 description 1
- RSPQPHNQIXKKLF-UHFFFAOYSA-N tert-butyl n-[3-[2-[(4-chloro-1h-indol-3-yl)sulfanyl]phenyl]propyl]-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)CCCC1=CC=CC=C1SC1=CNC2=CC=CC(Cl)=C12 RSPQPHNQIXKKLF-UHFFFAOYSA-N 0.000 description 1
- OYTMKUZFBMXZDU-UHFFFAOYSA-N tert-butyl n-[3-[2-[[5-(dimethylamino)-1h-indol-3-yl]sulfanyl]phenyl]propyl]-n-methylcarbamate Chemical compound C12=CC(N(C)C)=CC=C2NC=C1SC1=CC=CC=C1CCCN(C)C(=O)OC(C)(C)C OYTMKUZFBMXZDU-UHFFFAOYSA-N 0.000 description 1
- HOHHLHVHXGMKRR-UHFFFAOYSA-N tert-butyl n-[4-[2-(1h-indol-3-ylsulfanyl)phenyl]butyl]-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)CCCCC1=CC=CC=C1SC1=CNC2=CC=CC=C12 HOHHLHVHXGMKRR-UHFFFAOYSA-N 0.000 description 1
- LZGOPDBSUNVIRS-UHFFFAOYSA-N tert-butyl n-methyl-n-[2-(2-sulfanylphenyl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C)CCC1=CC=CC=C1S LZGOPDBSUNVIRS-UHFFFAOYSA-N 0.000 description 1
- PLPRZROSBXOMGC-UHFFFAOYSA-N tert-butyl n-methyl-n-[2-[2-(1-methylindol-3-yl)sulfanylphenyl]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C)CCC1=CC=CC=C1SC1=CN(C)C2=CC=CC=C12 PLPRZROSBXOMGC-UHFFFAOYSA-N 0.000 description 1
- AHKFTQMFYCGCMH-UHFFFAOYSA-N tert-butyl n-methyl-n-[2-[2-tri(propan-2-yl)silylsulfanylphenyl]ethyl]carbamate Chemical compound CC(C)[Si](C(C)C)(C(C)C)SC1=CC=CC=C1CCN(C)C(=O)OC(C)(C)C AHKFTQMFYCGCMH-UHFFFAOYSA-N 0.000 description 1
- BJYHPGZQQDSBNB-UHFFFAOYSA-N tert-butyl n-methyl-n-[3-(2-sulfanylphenyl)propyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C)CCCC1=CC=CC=C1S BJYHPGZQQDSBNB-UHFFFAOYSA-N 0.000 description 1
- JFLAFOXFVFRSRS-UHFFFAOYSA-N tert-butyl n-methyl-n-[3-[2-(1-methylindol-3-yl)sulfanylphenyl]propyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C)CCCC1=CC=CC=C1SC1=CN(C)C2=CC=CC=C12 JFLAFOXFVFRSRS-UHFFFAOYSA-N 0.000 description 1
- YGVSTLVFQRTVII-UHFFFAOYSA-N tert-butyl n-methyl-n-[3-[2-[(6-methylsulfonyl-1h-indol-3-yl)sulfanyl]phenyl]propyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C)CCCC1=CC=CC=C1SC1=CNC2=CC(S(C)(=O)=O)=CC=C12 YGVSTLVFQRTVII-UHFFFAOYSA-N 0.000 description 1
- AVHYWPVUUNHCPI-UHFFFAOYSA-N tert-butyl n-methyl-n-[4-(2-sulfanylphenyl)butyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C)CCCCC1=CC=CC=C1S AVHYWPVUUNHCPI-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 239000003174 triple reuptake inhibitor Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940009065 wellbutrin Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69200905P | 2005-06-17 | 2005-06-17 | |
| US692009P | 2005-06-17 | ||
| PCT/IB2006/002785 WO2006134499A2 (en) | 2005-06-17 | 2006-06-14 | 2-(1h-indolylsulfanyl)-aryl amine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2616095T3 true ES2616095T3 (es) | 2017-06-09 |
Family
ID=37532681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06808965.5T Active ES2616095T3 (es) | 2005-06-17 | 2006-06-14 | Derivados de 2-(1H-indolilsulfanil)-aril-amina |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1893575B1 (enExample) |
| JP (1) | JP5144507B2 (enExample) |
| KR (1) | KR20080027462A (enExample) |
| CN (1) | CN101238101A (enExample) |
| AR (1) | AR054394A1 (enExample) |
| AU (1) | AU2006257288A1 (enExample) |
| BR (1) | BRPI0611748A2 (enExample) |
| CA (1) | CA2611566C (enExample) |
| EA (1) | EA200800070A1 (enExample) |
| ES (1) | ES2616095T3 (enExample) |
| IL (1) | IL188064A0 (enExample) |
| MX (1) | MX2007014954A (enExample) |
| NO (1) | NO20080265L (enExample) |
| WO (1) | WO2006134499A2 (enExample) |
| ZA (1) | ZA200710885B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100286226A1 (en) * | 2007-09-24 | 2010-11-11 | H. Lundbeck A/S | Combination therapy related to serotonin dual action compounds |
| TW200938189A (en) * | 2008-03-13 | 2009-09-16 | Lundbeck & Co As H | [2-(6-flouro-1H-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders |
| US9000025B2 (en) | 2010-08-20 | 2015-04-07 | Amira Pharmaceuticals, Inc. | Autotaxin inhibitors and uses thereof |
| US9260416B2 (en) | 2011-05-27 | 2016-02-16 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
| ES2687481T3 (es) * | 2013-03-15 | 2018-10-25 | Chromocell Corporation | Moduladores del canal de sodio para el tratamiento del dolor |
| EP3046909A4 (en) | 2013-09-17 | 2017-03-29 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
| US9714240B2 (en) | 2013-09-17 | 2017-07-25 | Pharmakea, Inc. | Vinyl autotaxin inhibitor compounds |
| JP2016531874A (ja) | 2013-09-26 | 2016-10-13 | ファーマケア，インク． | オートタキシン阻害剤化合物 |
| CA2930737C (en) | 2013-11-22 | 2023-02-21 | Pharmakea, Inc. | Autotaxin inhibitor compounds |
| SG10201911204WA (en) | 2015-05-27 | 2020-02-27 | Pharmakea Inc | Autotaxin inhibitors and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4117129A (en) * | 1976-10-22 | 1978-09-26 | Warner-Lambert Company | Indolobenzoxazepines as cns depressants |
| ES2128281T1 (es) * | 1995-11-06 | 1999-05-16 | Gist Brocades Bv | Proceso de desesterificacion. |
| UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| TW200400177A (en) * | 2002-06-04 | 2004-01-01 | Wyeth Corp | 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands |
| JP4090491B2 (ja) * | 2003-12-23 | 2008-05-28 | ハー・ルンドベック・アクチエゼルスカベット | ２−（１ｈ−インドリルスルファニル）−ベンジルアミン誘導体 |
| AR052308A1 (es) * | 2004-07-16 | 2007-03-14 | Lundbeck & Co As H | Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto |
-
2006
- 2006-06-13 AR ARP060102491A patent/AR054394A1/es not_active Application Discontinuation
- 2006-06-14 JP JP2008516452A patent/JP5144507B2/ja not_active Expired - Fee Related
- 2006-06-14 WO PCT/IB2006/002785 patent/WO2006134499A2/en not_active Ceased
- 2006-06-14 CN CNA2006800218382A patent/CN101238101A/zh active Pending
- 2006-06-14 CA CA2611566A patent/CA2611566C/en not_active Expired - Fee Related
- 2006-06-14 MX MX2007014954A patent/MX2007014954A/es not_active Application Discontinuation
- 2006-06-14 KR KR1020077029334A patent/KR20080027462A/ko not_active Withdrawn
- 2006-06-14 EP EP06808965.5A patent/EP1893575B1/en active Active
- 2006-06-14 AU AU2006257288A patent/AU2006257288A1/en not_active Abandoned
- 2006-06-14 ES ES06808965.5T patent/ES2616095T3/es active Active
- 2006-06-14 EA EA200800070A patent/EA200800070A1/ru unknown
- 2006-06-14 ZA ZA200710885A patent/ZA200710885B/xx unknown
- 2006-06-14 BR BRPI0611748A patent/BRPI0611748A2/pt not_active IP Right Cessation
-
2007
- 2007-12-11 IL IL188064A patent/IL188064A0/en unknown
-
2008
- 2008-01-15 NO NO20080265A patent/NO20080265L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007014954A (es) | 2008-02-15 |
| EP1893575A2 (en) | 2008-03-05 |
| WO2006134499A2 (en) | 2006-12-21 |
| JP5144507B2 (ja) | 2013-02-13 |
| ZA200710885B (en) | 2009-03-25 |
| BRPI0611748A2 (pt) | 2016-11-22 |
| AR054394A1 (es) | 2007-06-20 |
| NO20080265L (no) | 2008-01-15 |
| JP2008546679A (ja) | 2008-12-25 |
| EP1893575B1 (en) | 2017-01-11 |
| IL188064A0 (en) | 2008-03-20 |
| CN101238101A (zh) | 2008-08-06 |
| AU2006257288A1 (en) | 2006-12-21 |
| KR20080027462A (ko) | 2008-03-27 |
| EA200800070A1 (ru) | 2008-04-28 |
| WO2006134499A3 (en) | 2007-04-12 |
| CA2611566A1 (en) | 2006-12-21 |
| CA2611566C (en) | 2011-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI92397C (fi) | Menetelmä valmistaa farmaseuttisesti käyttökelpoisia indolijohdoksia | |
| US7737170B2 (en) | Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS | |
| ES2616095T3 (es) | Derivados de 2-(1H-indolilsulfanil)-aril-amina | |
| ES2317266T3 (es) | Derivados de 2-(1h-indolilsulfanil)-arilamina para uso en el tratamiento de trastornos afectivos, dolor, hiperactividad con deficit de atencion e incontinencia urinaria por esfuerzo. | |
| US7629473B2 (en) | 2-(1H-indolylsulfanyl)-aryl amine derivatives | |
| US20090192213A1 (en) | Benzo[b]furane And Benzo[b]thiophene Derivatives | |
| ES2362237T3 (es) | Derivados de 2-(1h-indolilsulfanil)-bencilamina como isrs. | |
| KR100872023B1 (ko) | Ｓｓｒｉ로서 2-(1ｈ-인돌릴술파닐)-벤질 아민 유도체 |